%0 Journal Article
%T The continued EGFR-TKI with cytotoxic chemotherapy at progression¡ªpoison or medicine?
%A Chang Min Choi
%A Jae Cheol Lee
%A Shin-Kyo Yoon
%J SCIE-indexed Journal
%D 2018
%X EGFR tyrosine kinase inhibitors (TKI) have shown the efficacy in treatment of lung cancer patients with EGFR sensitizing mutations, and their use has led to a doubling of progression-free survival (PFS) and a lengthening of overall survival (OS) by more than 2 years. However, the emergence of resistance is inevitable, which creates new challenges for the management of patients with EGFR-mutant lung cancer (1). As several approaches after the development of resistance have been suggested, one of them is the continuation of EGFR-TKI with local therapy to aggravated lesions if necessary (2). This recommendation is based on some studies which showed the survival benefits by the continuation of EGFR-TKI compared with switching to cytotoxic chemotherapy (3,4). It implies that EGFR-TKI still has a role on the control of the EGFR-mutant lung cancer despite acquired resistance to EGFR-TKI. This phenomenon may be contributed by the capability of EGFR-TKI-sensitive clones to grow fast if EGFR-TKI removed and the relatively slow growth rate of resistant clones (5)
%U http://tlcr.amegroups.com/article/view/20391/15860